Skip to content | Change text size
 

Monash spin-off top innovator

30 November 2005

The Monash University spin-off company, Metabolic Pharmaceuticals Limited, has been named the nation's top innovator.

The medical research company, best known for its development of novel therapies for obesity-related diseases such as type 2 diabetes, topped the 2005 Research and Development and Intellectual Property Scoreboard list of 50 Australian innovators.

The index was put together by the Intellectual Property Research Institute of Australia, business analysts, IBIS World, IP Australia and the Melbourne Institute of Applied Economic and Social Research.

Dr Roland Scollay, CEO of Metabolic, said it was great recognition of the company's progress.

"I am very pleased to hear that Metabolic has been ranked number one in the index," he said.

"It's not always easy to explain the value of our intellectual property or the quality of our research and development to the public, but this innovation index would seem to confirm both areas in an entirely objective manner."

The companies listed in the top 50 were ranked by the contribution of their innovative activity to their asset value by aggregating research and development spending as well as patent, trade mark and design applications.

Metabolic ranked ahead of past winner Cochlear Ltd, which dropped to 23rd in the rankings. Meat and Livestock Australia came second.